Analyst Rating Update on Illumina (ILMN)

Illumina (ILMN) : 4 brokerage houses believe that Illumina (ILMN) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 9 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Illumina (ILMN). Zacks Investment Research suggests a Buy with a rank of 2. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 15 Wall Street Analysts endorse the stock as a Buy with a rating of 2.49.

Illumina (ILMN) : Currently there are 11 street experts covering Illumina (ILMN) stock. The most bullish and bearish price target for the stock is $200 and $115 respectively for the short term. The average price target of all the analysts comes to $156.27. The estimated standard deviation from the target is $24.27.

Company shares have received an average consensus rating of Hold for the current week


Illumina (NASDAQ:ILMN): The stock opened at $166.94 on Wednesday but the bulls could not build on the opening and the stock topped out at $167.14 for the day. The stock traded down to $164.69 during the day, due to lack of any buying support eventually closed down at $165.05 with a loss of -1.12% for the day. The stock had closed at $166.92 on the previous day. The total traded volume was 947,582 shares.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.